Corient Private Wealth LLC Has $12.64 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Corient Private Wealth LLC boosted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 4.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 197,257 shares of the company’s stock after purchasing an additional 8,894 shares during the period. Corient Private Wealth LLC’s holdings in AstraZeneca were worth $12,642,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of AZN. Albion Financial Group UT boosted its position in AstraZeneca by 68.9% during the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after purchasing an additional 248 shares during the last quarter. Groupama Asset Managment boosted its position in AstraZeneca by 22.9% during the third quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock valued at $42,000 after purchasing an additional 101,225 shares during the last quarter. Versant Capital Management Inc boosted its position in AstraZeneca by 2,618.5% during the fourth quarter. Versant Capital Management Inc now owns 734 shares of the company’s stock valued at $48,000 after purchasing an additional 707 shares during the last quarter. Crews Bank & Trust acquired a new stake in shares of AstraZeneca in the fourth quarter valued at approximately $55,000. Finally, Golden State Wealth Management LLC acquired a new stake in shares of AstraZeneca in the fourth quarter valued at approximately $55,000. 20.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Morgan Stanley assumed coverage on AstraZeneca in a research report on Wednesday, February 12th. They issued an “overweight” rating for the company. UBS Group raised AstraZeneca from a “neutral” rating to a “buy” rating in a research report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Stock Performance

NASDAQ:AZN opened at $76.32 on Thursday. The stock has a market cap of $236.68 billion, a P/E ratio of 33.77, a PEG ratio of 1.42 and a beta of 0.41. The stock has a 50 day simple moving average of $72.47 and a 200 day simple moving average of $72.16. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. AstraZeneca PLC has a 1-year low of $62.75 and a 1-year high of $87.68.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.05 earnings per share for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. Research analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Monday, March 24th. Shareholders of record on Friday, February 21st will be issued a $1.03 dividend. The ex-dividend date of this dividend is Friday, February 21st. This is a boost from AstraZeneca’s previous semi-annual dividend of $0.49. This represents a yield of 2%. AstraZeneca’s payout ratio is currently 91.15%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.